Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

1st Immunotherapy of Cancer Conference (ITOC 1)

12 - 14 Mar 2014

TBA, Munich, Germany

Emerging pathways in immunotherapy

Prof Christopher Höller - Medical University of Vienna, Vienna, Austria

Emerging pathways in immunotherapy ( Prof Christopher Höller - Medical University of Vienna, Vienna, Austria )

Checkpoint blockade: a concept or already a reality?

Prof Paolo Ascierto - National Cancer Institute 'Foundazione G. Pascale'...

Checkpoint blockade: a concept or already a reality? ( Prof Paolo Ascierto - National Cancer Institute 'Foundazione G. Pascale', Naples, Italy )

Cancer evasion of the immune system: the fundamentals

Prof Pedro Romero - Ludwig Institute for Cancer Research, Lausanne, Switzerland

Cancer evasion of the immune system: the fundamentals ( Prof Pedro Romero - Ludwig Institute for Cancer Research, Lausanne, Switzerland )

Biomarker development for ipilimumab and prostate GVAX treatment

Prof Tanja D. de Gruijl - VU University Medical Centre, Amsterdam, The...

Biomarker development for ipilimumab and prostate GVAX treatment ( Prof Tanja D. de Gruijl - VU University Medical Centre, Amsterdam, The Netherlands )

Toll like receptor 7 agonists for cancer immunotherapy

Prof Stefan Endres - Ludwig-Maximilians-Universität, Munich, Germany

Toll like receptor 7 agonists for cancer immunotherapy ( Prof Stefan Endres - Ludwig-Maximilians-Universität, Munich, Germany )

Maintenance therapy of metastatic colorectal carcinoma with the TLR-9 agonist...

Prof Jorge Riera-Knorrenschild - University Clinic Giessen and Marburg, Marburg...

Maintenance therapy of metastatic colorectal carcinoma with the TLR-9 agonist MGN1703 ( Prof Jorge Riera-Knorrenschild - University Clinic Giessen and Marburg, Marburg, Germany )

Adoptive cell therapy of melanoma with autologous tumour infiltrating...

Prof Inge Marie Svane - Herlev Hospital, Copenhagen University, Copenhagen...

Adoptive cell therapy of melanoma with autologous tumour infiltrating lymphocytes ( Prof Inge Marie Svane - Herlev Hospital, Copenhagen University, Copenhagen, Denmark )

The 1st Immunotherapy of Cancer Conference (ITOC)

Prof Heinz Zwierina - Innsbruck Medical University, Innsbruck, Austria

The 1st Immunotherapy of Cancer Conference (ITOC) ( Prof Heinz Zwierina - Innsbruck Medical University, Innsbruck, Austria )

Reasons for combining immunotherapy with chemo to enhance anti tumour response

Prof Angus Dalgleish - St George's, University of London, London, UK

Reasons for combining immunotherapy with chemo to enhance anti tumour response ( Prof Angus Dalgleish - St George's, University of London, London, UK )

High-affinity CD20-specific TCRs suitable for adoptive immunotherapy isolated...

Dr Lorenz Jahn - Leiden Univeristy Medical Centre, Leiden, The Netherlands

High-affinity CD20-specific TCRs suitable for adoptive immunotherapy isolated from the allo-repertoire using reverse immunology ( Dr Lorenz Jahn - Leiden Univeristy Medical Centre, Leiden, The Netherlands )

Molecular pathways associated with immune modulation and thalidomide analogues

Dr Rajesh Chopra - Vice President of Translational and Early Drug Development...

Molecular pathways associated with immune modulation and thalidomide analogues ( Dr Rajesh Chopra - Vice President of Translational and Early Drug Development, Celgene )

Dendritic cell vaccination combined with CTLA4 blockade

Dr Kris Thielemans - Medical School of the VUB, Brussels, Belgium

Dendritic cell vaccination combined with CTLA4 blockade ( Dr Kris Thielemans - Medical School of the VUB, Brussels, Belgium )

mRNA-based cancer vaccines

Dr Karl-Josef Kallen - Principal Scientific Fellow, CureVac Gmbh

mRNA-based cancer vaccines ( Dr Karl-Josef Kallen - Principal Scientific Fellow, CureVac Gmbh )

Immuno-biological properties of human cancer stem cells

Dr Cristina Maccalli - NIBIT (Italian Network for Biotherapy of Tumours), Siena...

Immuno-biological properties of human cancer stem cells ( Dr Cristina Maccalli - NIBIT (Italian Network for Biotherapy of Tumours), Siena, Italy )

Novel CEA-targeted IL2 variant immunocytokine for immunotherapy of cancer

Dr Christian Klein - Head of Oncology Programs, Discovery Oncology, Roche...

Novel CEA-targeted IL2 variant immunocytokine for immunotherapy of cancer ( Dr Christian Klein - Head of Oncology Programs, Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland )

More from ecancer